molecules-logo

Journal Browser

Journal Browser

The State-of-the-Art in Improving the Antitumor Efficacy of Platinum Drugs

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 20 May 2025 | Viewed by 2461

Special Issue Editors


E-Mail Website
Guest Editor
Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy
Interests: bioinorganic chemistry; bioorganometallic chemistry; medicinal inorganic chemistry; biologically active transition metal complexes; metal-based (in particular, platinum) anticancer agents; drug targeting and delivery; inorganic electrochemistry
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Dipartimento per lo Sviluppo Sostenibile e la Transizione Ecologica, Università del Piemonte Orientale, Piazza S. Eusebio 5, 13100 Vercelli, Italy
Interests: bioinorganic chemistry; coordination compounds; Pt complexes as potential antitumor drugs; drug targeting and delivery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Despite the development of personalized medicine within oncology, traditional platinum-based drugs are still difficult to replace, even considering their weaknesses. However, we can try to improve them with more suitable pharmacological properties. This goal can only be achieved with an approach that is multi-, inter-, and trans-disciplinary at the same time.

The aim of this Special Issue is precisely to stimulate a dialogue between different disciplines to collect new ideas and suggestions from diverse areas of science, independently from the classification of new drugs. In this spirit ‘Pharmaceutics’ and ‘Molecules’ reached a unanimous decision to create a joint Special Issue titled “The State-of-the-Art in Improving the Antitumor Efficacy of Platinum Drugs”. The unifying goal of the Special Issue is contained within these words: to share ideas, positive experiences, and (why not?) failures showing the ability of platinum-based anticancer agents to kill cancer cells with biological mechanisms that are different from those used by the reference drug cisplatin, to bypass chemoresistance, to be activated preferentially at the tumor site only, to be delivered more selectively to the final target, and to have a final target that is not only DNA. These are just some suggestions, but they are not binding. For example, one possible way of improving the antitumor efficacy of platinum drugs is… not to use platinum! For this reason, candidate drugs containing metals aside from platinum are also welcome. Original or review articles concerning the above-said topics and studies on computer-aided drug design, in silico studies, drug repurposing, pharmacokinetics, and pharmacodynamics are greatly encouraged.

We look forward to receiving your contributions.

You may choose our Joint Special Issue in Pharmaceutics.

Prof. Dr. Mauro Ravera
Dr. Elisabetta Gabano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bioinorganic chemistry
  • metal-based drugs
  • pt coordination compounds
  • pharmacodynamics
  • pharmacokinetics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 2416 KiB  
Article
Sustainable Nanomedicine: Enhancement of Asplatin’s Cytotoxicity In Vitro and In Vivo Using Green-Synthesized Zinc Oxide Nanoparticles Formed via Microwave-Assisted and Gambogic Acid-Mediated Processes
by Hatem A. F. M. Hassan, Nada K. Sedky, Mohamed S. Nafie, Noha Khalil Mahdy, Iten M. Fawzy, Toka Waleed Fayed, Eduard Preis, Udo Bakowsky and Sherif Ashraf Fahmy
Molecules 2024, 29(22), 5327; https://doi.org/10.3390/molecules29225327 - 12 Nov 2024
Cited by 1 | Viewed by 2075
Abstract
Chemoresistance encountered using conventional chemotherapy demands novel treatment approaches. Asplatin (Asp), a novel platinum (IV) prodrug designed to release cisplatin and aspirin in a reductive environment, has demonstrated high cytotoxicity at reduced drug resistance. Herein, we investigated the ability of green-synthesized nanocarriers to [...] Read more.
Chemoresistance encountered using conventional chemotherapy demands novel treatment approaches. Asplatin (Asp), a novel platinum (IV) prodrug designed to release cisplatin and aspirin in a reductive environment, has demonstrated high cytotoxicity at reduced drug resistance. Herein, we investigated the ability of green-synthesized nanocarriers to enhance Asp’s efficacy. Zinc oxide nanoparticles (ZnO-NPs) were synthesized using a green microwave-assisted method with the reducing and capping agent gambogic acid (GA). These nanoparticles were then loaded with Asp, yielding Asp@ZnO-NPs. Transmission electron microscopy was utilized to study the morphological features of ZnO-NPs. Cell viability studies conducted on MDA-MB-231 breast cancer cells demonstrated the ability of the Asp@ZnO-NPs treatment to significantly decrease Asp’s half-maximal inhibitory concentration (IC50) (5 ± 1 µg/mL). This was further demonstrated using flow cytometric analysis that revealed the capacity of Asp@ZnO-NPs treatment to significantly increase late apoptotic fractions. Furthermore, in vivo studies carried out using solid Ehrlich carcinoma-bearing mice showed significant tumor volume reduction with the Asp@ZnO-NPs treatment (156.3 ± 7.6 mm3), compared to Asp alone (202.3 ± 8.4 mm3) and untreated controls (342.6 ± 10.3 mm3). The histopathological analysis further demonstrated the increased necrosis in Asp@ZnO-NPs-treated group. This study revealed that Asp@ZnO-NPs, synthesized using an eco-friendly approach, significantly enhanced Asp’s anticancer activity, offering a sustainable solution for potent anticancer formulations. Full article
Show Figures

Figure 1

Back to TopTop